Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: phase 1/2 open-label study of selinexor formulations, hepatic impairment pharmacokinetics, and combination therapy in advanced solid tumors
MOH_2019-12-08_008505Phase 2Recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and Nonhematologic neoplasms (7 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoints: Bioavailability and bioequivalence of two selinexor formulations, Selinexor pharmacokinetics in normal and impaired hepatic function and 1 more. Started Nov 2019; status: recruiting.
02
Drugs
selinexor
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2019-12-08_008505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-08_008505.